Is Biomind Labs Inc. (BMNDF) a Buy, Sell, or Hold?
Biomind Labs Inc.
OTC:BMNDF
$0.1 USD
$0.01 (8.64%)
- Volume
- 1.21K
- Average Volume
- 210
- Market Capitalization
- $7.76M
- P/E Ratio
- -8.70
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $0.15
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.01
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Alejandro Antalich |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BMNDF |
| CUSIP | 090702101 |
| CIK | None |
| Web | https://www.biomindlabs.com |
| Phone | +1 647 360 4055 |
| Currency | USD |
| Employees | 5 |
| Country | UY |
Liquidity
| Debt-to-Equity Ratio | -0.43 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Cash Ratio | 0.01 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | 0.00 |
| Price / Cash Flow | -57.80 |
| Price / Book | -4.28 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.0111 |
| Trailing P/E Ratio | -8.70 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-865.3K |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 54.12% |
| Return on Assets | -6212.83% |
Financials Score
| AltmanZ Score | -1877.71 |
| Piotroski Score | 1.00 |
| Working Capital | -1.81M |
| Total Assets | 14.39K |
| Ebit | -820.53K |
| Market Cap | 9.31M |
| Total Liabilities | 1.83M |
Poll Results
About Biomind Labs Inc. (OTC:BMNDF) Stock
Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression. Another key candidate, BMND08, a derivative of 5-Methoxy-N,N-dimethyltryptamine, is also in Phase II trials, addressing depression and anxiety specifically in patients experiencing cognitive decline associated with Alzheimer's disease. The company's broader development portfolio includes early-stage and preclinical candidates such as BMND02 for fibromyalgia, BMND03 for substance use disorders, BMND05 for persistent pain management, BMND06 for inflammato ... ry conditions, and BMND07 for severe clinical depression. Biomind Labs Inc. maintains its headquarters in Canelones, Uruguay.
2026-04-20 08:30:00
A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage bio-pharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today welcomes the historic executive order signed by President Trump to accelerate research, regulatory pathways, and patient access to psychedelic treatments. This landmark policy shift marks a turning point in U.S. healthcare and drug policy, one that aligns directly with Biomind's long-term vision: to redefine how the world treats mental health and brain-related conditions.
Frequently Asked Questions
-
What is the current Biomind Labs Inc. (BMNDF) stock price?
-
Biomind Labs Inc.(OTC:BMNDF) stock price is $0.1 in the last trading session. During the trading session, BMNDF stock reached the peak price of $0.15 while $0.011 was the lowest point it dropped to. The percentage change in BMNDF stock occurred in the recent session was 8.64% while the dollar amount for the price change in BMNDF stock was $0.01.
-
BMNDF's industry and sector of operation?
-
The OTC listed BMNDF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BMNDF?
-
Oscar Alejandro León Bentancor | Chief Financial Officer & Director
Alejandro Antalich | Chief Executive Officer & Director
Paola Diaz Dellavalle | Chief Scientific Officer
Martin Daners | Head of Quality Assurance & Regulatory Affairs
Juan Presa | Chief Legal Officer -
How many employees does BMNDF have?
-
Number of BMNDF employees currently stands at 5. BMNDF operates from Building Ceibo Of. 002, Canelones, None None, UY.
-
Link for BMNDF official website?
-
Official Website of BMNDF is: https://www.biomindlabs.com
-
How do I contact BMNDF?
-
BMNDF could be contacted at phone #+1 647 360 4055 and can also be accessed through its website. BMNDF operates from Building Ceibo Of. 002, Canelones, None None, UY.
-
How many shares of BMNDF are traded daily?
-
The average number of BMNDF shares traded daily for last 3 months was 210.
-
What is the market cap of BMNDF currently?
-
The market value of BMNDF currently stands at $7.76M with its latest stock price at $0.1